Contraception

Key clinical point: The overall rate of uterine perforation after intrauterine device (IUD) insertion was less than 1%, but higher with placement at 4-8 weeks postpartum compared to 9-36 weeks postpartum.

Major finding:  After adjusting for multiple variables, perforation rates associated with IUDs were significantly higher when placed at 4-8 weeks vs. 9-36 weeks postpartum (0.78% versus 0.46%, P = .001). Expulsion rates were low and similar between the early and late placement groups (1.02 vs. 1.17).

Study details: The data come from a retrospective cohort study of 24,959 women who underwent insertion of an intrauterine device at a single center. A total of 430 patients had confirmed complications; 157 of these were uterine perforations and 273 were intrauterine device expulsions.

Disclosures: The study received no outside funding. Lead author Dr. Ramos-Rivera had no financial conflicts to disclose. A coauthor is supported by the NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development.

Source: Ramos-Rivera M et al. Am J Obstet Gynecol. 2021 Aug 27. doi: 10.1016/j.ajog.2021.08.028.

Key clinical point: The overall rate of uterine perforation after intrauterine device (IUD) insertion was less than 1%, but higher with placement at 4-8 weeks postpartum compared to 9-36 weeks postpartum.

Major finding:  After adjusting for multiple variables, perforation rates associated with IUDs were significantly higher when placed at 4-8 weeks vs. 9-36 weeks postpartum (0.78% versus 0.46%, P = .001). Expulsion rates were low and similar between the early and late placement groups (1.02 vs. 1.17).

Study details: The data come from a retrospective cohort study of 24,959 women who underwent insertion of an intrauterine device at a single center. A total of 430 patients had confirmed complications; 157 of these were uterine perforations and 273 were intrauterine device expulsions.

Disclosures: The study received no outside funding. Lead author Dr. Ramos-Rivera had no financial conflicts to disclose. A coauthor is supported by the NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development.

Source: Ramos-Rivera M et al. Am J Obstet Gynecol. 2021 Aug 27. doi: 10.1016/j.ajog.2021.08.028.

Key clinical point: The overall rate of uterine perforation after intrauterine device (IUD) insertion was less than 1%, but higher with placement at 4-8 weeks postpartum compared to 9-36 weeks postpartum.

Major finding:  After adjusting for multiple variables, perforation rates associated with IUDs were significantly higher when placed at 4-8 weeks vs. 9-36 weeks postpartum (0.78% versus 0.46%, P = .001). Expulsion rates were low and similar between the early and late placement groups (1.02 vs. 1.17).

Study details: The data come from a retrospective cohort study of 24,959 women who underwent insertion of an intrauterine device at a single center. A total of 430 patients had confirmed complications; 157 of these were uterine perforations and 273 were intrauterine device expulsions.

Disclosures: The study received no outside funding. Lead author Dr. Ramos-Rivera had no financial conflicts to disclose. A coauthor is supported by the NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development.

Source: Ramos-Rivera M et al. Am J Obstet Gynecol. 2021 Aug 27. doi: 10.1016/j.ajog.2021.08.028.

Key clinical point: No significant associations were noted between contraception choice and age, previous pregnancies, or social determinants of health, but nearly 100% of women opted for some form of contraception following a pregnancy termination.

Major finding:  Prior to pregnancy termination, 58.5% of women reported not using contraception, and 22.4% reported using a barrier or fertility awareness. After pregnancy termination, 99.7% of women chose a form of contraception, and 95.2% chose a more effective method than what they had been using. After 6 months, 85.8% were still using contraception, and 37.8% were still using a more effective method.

Study details: The data come from a cross-sectional study of 400 women who underwent termination of pregnancy over a 2-year period. Information about contraception choice was collected before pregnancy termination, at the time of termination, and at 6 months following termination.

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Source: Smith SN et al. J Obstet Gynaecol Can. 2021 Aug 27. doi: 10.1016/j.jogc.2021.07.012.

Key clinical point: No significant associations were noted between contraception choice and age, previous pregnancies, or social determinants of health, but nearly 100% of women opted for some form of contraception following a pregnancy termination.

Major finding:  Prior to pregnancy termination, 58.5% of women reported not using contraception, and 22.4% reported using a barrier or fertility awareness. After pregnancy termination, 99.7% of women chose a form of contraception, and 95.2% chose a more effective method than what they had been using. After 6 months, 85.8% were still using contraception, and 37.8% were still using a more effective method.

Study details: The data come from a cross-sectional study of 400 women who underwent termination of pregnancy over a 2-year period. Information about contraception choice was collected before pregnancy termination, at the time of termination, and at 6 months following termination.

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Source: Smith SN et al. J Obstet Gynaecol Can. 2021 Aug 27. doi: 10.1016/j.jogc.2021.07.012.

Key clinical point: No significant associations were noted between contraception choice and age, previous pregnancies, or social determinants of health, but nearly 100% of women opted for some form of contraception following a pregnancy termination.

Major finding:  Prior to pregnancy termination, 58.5% of women reported not using contraception, and 22.4% reported using a barrier or fertility awareness. After pregnancy termination, 99.7% of women chose a form of contraception, and 95.2% chose a more effective method than what they had been using. After 6 months, 85.8% were still using contraception, and 37.8% were still using a more effective method.

Study details: The data come from a cross-sectional study of 400 women who underwent termination of pregnancy over a 2-year period. Information about contraception choice was collected before pregnancy termination, at the time of termination, and at 6 months following termination.

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Source: Smith SN et al. J Obstet Gynaecol Can. 2021 Aug 27. doi: 10.1016/j.jogc.2021.07.012.

Key clinical point: In 2019, 41% of health care providers prescribed regular contraception at the same time as emergency contraception; this percentage was an increase from 2013-2014, but falls short of the US Selected Practice Recommendations for Contraceptive Use, first released in 2013.

Major finding:  Health care providers in 2019 were more likely than health care providers in 2013 and 2014 to prescribe or provide contraception when providing emergency contraception (adjusted prevalence ratio 1.26) and to provide a copper intrauterine device (adjusted prevalence ratio 3.87). A total of 41% frequently provided or prescribed regular contraception at the time of providing emergency contraceptive pills (ECP), 16% of providers in 2019 frequently provided an advance prescription for ECPs, 8% provided a copper intrauterine device as emergency contraception, and 7% provided an advance supply of ECPs.

Study details: The data come from two cross-sectional surveys mailed to office-based physicians and public-sector health care providers in the United States in 2013-14 (2,060 respondents) and 2019 (1,420 respondents).

Disclosures: The study was published on behalf of the Jacobs Institute of Women’s Health. The researchers had no financial conflicts to disclose.

Source: Pagano HP et al. Womens Health Issues. 2021 Sep 9. doi: 10.1016/j.whi.2021.07.006.

Key clinical point: In 2019, 41% of health care providers prescribed regular contraception at the same time as emergency contraception; this percentage was an increase from 2013-2014, but falls short of the US Selected Practice Recommendations for Contraceptive Use, first released in 2013.

Major finding:  Health care providers in 2019 were more likely than health care providers in 2013 and 2014 to prescribe or provide contraception when providing emergency contraception (adjusted prevalence ratio 1.26) and to provide a copper intrauterine device (adjusted prevalence ratio 3.87). A total of 41% frequently provided or prescribed regular contraception at the time of providing emergency contraceptive pills (ECP), 16% of providers in 2019 frequently provided an advance prescription for ECPs, 8% provided a copper intrauterine device as emergency contraception, and 7% provided an advance supply of ECPs.

Study details: The data come from two cross-sectional surveys mailed to office-based physicians and public-sector health care providers in the United States in 2013-14 (2,060 respondents) and 2019 (1,420 respondents).

Disclosures: The study was published on behalf of the Jacobs Institute of Women’s Health. The researchers had no financial conflicts to disclose.

Source: Pagano HP et al. Womens Health Issues. 2021 Sep 9. doi: 10.1016/j.whi.2021.07.006.

Key clinical point: In 2019, 41% of health care providers prescribed regular contraception at the same time as emergency contraception; this percentage was an increase from 2013-2014, but falls short of the US Selected Practice Recommendations for Contraceptive Use, first released in 2013.

Major finding:  Health care providers in 2019 were more likely than health care providers in 2013 and 2014 to prescribe or provide contraception when providing emergency contraception (adjusted prevalence ratio 1.26) and to provide a copper intrauterine device (adjusted prevalence ratio 3.87). A total of 41% frequently provided or prescribed regular contraception at the time of providing emergency contraceptive pills (ECP), 16% of providers in 2019 frequently provided an advance prescription for ECPs, 8% provided a copper intrauterine device as emergency contraception, and 7% provided an advance supply of ECPs.

Study details: The data come from two cross-sectional surveys mailed to office-based physicians and public-sector health care providers in the United States in 2013-14 (2,060 respondents) and 2019 (1,420 respondents).

Disclosures: The study was published on behalf of the Jacobs Institute of Women’s Health. The researchers had no financial conflicts to disclose.

Source: Pagano HP et al. Womens Health Issues. 2021 Sep 9. doi: 10.1016/j.whi.2021.07.006.

Key clinical point: Use of progestin-releasing long-acting reversible contraceptives (LARC) was linked to weight gain in nulliparous adolescents aged 14-19 years; 25% of the study population was obese, and significant interaction effect (P = .017) showed a greater increase in BMI in this subset of participants who used an LARC compared to a copper intrauterine device (IUD).

Major finding:  The mean change in body mass index among teen girls who used LARC was an increase of 0.73 kg/m²; BMI increases averaged 0.92 kg/m² for those who used an etornogestrel subdermal implant plus levonorgestrel intrauterine device (LNG-IUD) and 0.37 kg/m² in those who used a copper IUD.

Study details: The data come from a retrospective cohort study of 196 adolescents aged 14-19 years who underwent placement of long-acting reversible contraceptive devices.

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Source: Scott N et al. J Pediatr Adolesc Gynecol. 2021 Aug 10. doi: 10.1016/j.jpag.2021.08.004.

Key clinical point: Use of progestin-releasing long-acting reversible contraceptives (LARC) was linked to weight gain in nulliparous adolescents aged 14-19 years; 25% of the study population was obese, and significant interaction effect (P = .017) showed a greater increase in BMI in this subset of participants who used an LARC compared to a copper intrauterine device (IUD).

Major finding:  The mean change in body mass index among teen girls who used LARC was an increase of 0.73 kg/m²; BMI increases averaged 0.92 kg/m² for those who used an etornogestrel subdermal implant plus levonorgestrel intrauterine device (LNG-IUD) and 0.37 kg/m² in those who used a copper IUD.

Study details: The data come from a retrospective cohort study of 196 adolescents aged 14-19 years who underwent placement of long-acting reversible contraceptive devices.

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Source: Scott N et al. J Pediatr Adolesc Gynecol. 2021 Aug 10. doi: 10.1016/j.jpag.2021.08.004.

Key clinical point: Use of progestin-releasing long-acting reversible contraceptives (LARC) was linked to weight gain in nulliparous adolescents aged 14-19 years; 25% of the study population was obese, and significant interaction effect (P = .017) showed a greater increase in BMI in this subset of participants who used an LARC compared to a copper intrauterine device (IUD).

Major finding:  The mean change in body mass index among teen girls who used LARC was an increase of 0.73 kg/m²; BMI increases averaged 0.92 kg/m² for those who used an etornogestrel subdermal implant plus levonorgestrel intrauterine device (LNG-IUD) and 0.37 kg/m² in those who used a copper IUD.

Study details: The data come from a retrospective cohort study of 196 adolescents aged 14-19 years who underwent placement of long-acting reversible contraceptive devices.

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Source: Scott N et al. J Pediatr Adolesc Gynecol. 2021 Aug 10. doi: 10.1016/j.jpag.2021.08.004.

Key clinical point: A review of 58 YouTube videos on removal of long-acting reversible contraception showed more than 4 million views overall; reasons for removal included negative side effects, fear of side effects, and desire for pregnancy.

Major finding:  Most of the women who created the 58 videos were white (53%), 31% were Black, and 14% were Latina. Of these, 56 of 58 successfully removed their device and described the experience as positive in terms of ease of removal.

Study details: The data come from a review of 58 videos on self-removal of long-acting reversible contraception based on YouTube keyword searches. The videos included 48 individuals removing an intrauterine device and 10 removing an implant.

Disclosures: The study was supported by the Eunice Kennedy Shriver National Institute of Child Health and Human Development and by the National Science Foundation Graduate Research Fellowship Program. The researchers had no financial conflicts to disclose.

Source: Broussard K and Becker A. Contraception. 2021 Aug 13. doi: 10.1016/j.contraception.2021.08.002.

Key clinical point: A review of 58 YouTube videos on removal of long-acting reversible contraception showed more than 4 million views overall; reasons for removal included negative side effects, fear of side effects, and desire for pregnancy.

Major finding:  Most of the women who created the 58 videos were white (53%), 31% were Black, and 14% were Latina. Of these, 56 of 58 successfully removed their device and described the experience as positive in terms of ease of removal.

Study details: The data come from a review of 58 videos on self-removal of long-acting reversible contraception based on YouTube keyword searches. The videos included 48 individuals removing an intrauterine device and 10 removing an implant.

Disclosures: The study was supported by the Eunice Kennedy Shriver National Institute of Child Health and Human Development and by the National Science Foundation Graduate Research Fellowship Program. The researchers had no financial conflicts to disclose.

Source: Broussard K and Becker A. Contraception. 2021 Aug 13. doi: 10.1016/j.contraception.2021.08.002.

Key clinical point: A review of 58 YouTube videos on removal of long-acting reversible contraception showed more than 4 million views overall; reasons for removal included negative side effects, fear of side effects, and desire for pregnancy.

Major finding:  Most of the women who created the 58 videos were white (53%), 31% were Black, and 14% were Latina. Of these, 56 of 58 successfully removed their device and described the experience as positive in terms of ease of removal.

Study details: The data come from a review of 58 videos on self-removal of long-acting reversible contraception based on YouTube keyword searches. The videos included 48 individuals removing an intrauterine device and 10 removing an implant.

Disclosures: The study was supported by the Eunice Kennedy Shriver National Institute of Child Health and Human Development and by the National Science Foundation Graduate Research Fellowship Program. The researchers had no financial conflicts to disclose.

Source: Broussard K and Becker A. Contraception. 2021 Aug 13. doi: 10.1016/j.contraception.2021.08.002.

Key clinical point: Among young women, the average Pregnancy Risk Index (PRI) was 4.75; individuals using teratogenic medication had the lowest PRI (0.32); 88% of these individuals used reversible contraception and 31% used long-acting reversible contraception.

Major finding:  Approximately 73% of sexually active young women received contraceptive counseling, which was associated with a significantly increased use of reversible and dual contraception, but not long-acting reversible contraception. At last reported vaginal sex, 65% reported using condoms, 49% reported using reversible contraception, and 12% reported using long-acting reversible contraception.

Study details: The data come from a cross-sectional survey of 177 hospitalized females aged 14 to 21 years at two academic medical centers; the surveys assessed sexual health behaviors, contraceptive use, contraceptive counseling, and pregnancy complications. Researchers calculated the Pregnancy Risk Index (the number per 100 individuals who will become pregnant in the next year).

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Source: Hunt JA et al. Hosp Pediatr. 2021 Sep 13. doi: 10.1542/hpeds.2021-005810.

Key clinical point: Among young women, the average Pregnancy Risk Index (PRI) was 4.75; individuals using teratogenic medication had the lowest PRI (0.32); 88% of these individuals used reversible contraception and 31% used long-acting reversible contraception.

Major finding:  Approximately 73% of sexually active young women received contraceptive counseling, which was associated with a significantly increased use of reversible and dual contraception, but not long-acting reversible contraception. At last reported vaginal sex, 65% reported using condoms, 49% reported using reversible contraception, and 12% reported using long-acting reversible contraception.

Study details: The data come from a cross-sectional survey of 177 hospitalized females aged 14 to 21 years at two academic medical centers; the surveys assessed sexual health behaviors, contraceptive use, contraceptive counseling, and pregnancy complications. Researchers calculated the Pregnancy Risk Index (the number per 100 individuals who will become pregnant in the next year).

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Source: Hunt JA et al. Hosp Pediatr. 2021 Sep 13. doi: 10.1542/hpeds.2021-005810.

Key clinical point: Among young women, the average Pregnancy Risk Index (PRI) was 4.75; individuals using teratogenic medication had the lowest PRI (0.32); 88% of these individuals used reversible contraception and 31% used long-acting reversible contraception.

Major finding:  Approximately 73% of sexually active young women received contraceptive counseling, which was associated with a significantly increased use of reversible and dual contraception, but not long-acting reversible contraception. At last reported vaginal sex, 65% reported using condoms, 49% reported using reversible contraception, and 12% reported using long-acting reversible contraception.

Study details: The data come from a cross-sectional survey of 177 hospitalized females aged 14 to 21 years at two academic medical centers; the surveys assessed sexual health behaviors, contraceptive use, contraceptive counseling, and pregnancy complications. Researchers calculated the Pregnancy Risk Index (the number per 100 individuals who will become pregnant in the next year).

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Source: Hunt JA et al. Hosp Pediatr. 2021 Sep 13. doi: 10.1542/hpeds.2021-005810.

Key clinical point: Women with potential contraindications to estrogen were significantly more likely than those without contraindication to use permanent contraception or no contraception

Major finding:  A total of 15% of women with potential contraindications to estrogen reported using the pill, patch, or ring, compared to 20% of women with no potential contraindications to estrogen. Women with contraindications to estrogen also were significantly more likely than those without contraindications to use permanent contraception (odds ratio vs. patch, pill, or ring 1.48) or no contraception (OR vs. patch, pill, or ring 1.37). 

Study details: The data come from surveys of 32,098 women aged 18-44 years who participated in the 2017 Behavioral Risk Factor Surveillance System, 16% of whom had at least one potential contraindication to estrogen.

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Source: Erly SJ et al. J Womens Health. 2021 Sep 1. doi: 10.1089/jwh.2020.8905. 

Key clinical point: Women with potential contraindications to estrogen were significantly more likely than those without contraindication to use permanent contraception or no contraception

Major finding:  A total of 15% of women with potential contraindications to estrogen reported using the pill, patch, or ring, compared to 20% of women with no potential contraindications to estrogen. Women with contraindications to estrogen also were significantly more likely than those without contraindications to use permanent contraception (odds ratio vs. patch, pill, or ring 1.48) or no contraception (OR vs. patch, pill, or ring 1.37). 

Study details: The data come from surveys of 32,098 women aged 18-44 years who participated in the 2017 Behavioral Risk Factor Surveillance System, 16% of whom had at least one potential contraindication to estrogen.

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Source: Erly SJ et al. J Womens Health. 2021 Sep 1. doi: 10.1089/jwh.2020.8905. 

Key clinical point: Women with potential contraindications to estrogen were significantly more likely than those without contraindication to use permanent contraception or no contraception

Major finding:  A total of 15% of women with potential contraindications to estrogen reported using the pill, patch, or ring, compared to 20% of women with no potential contraindications to estrogen. Women with contraindications to estrogen also were significantly more likely than those without contraindications to use permanent contraception (odds ratio vs. patch, pill, or ring 1.48) or no contraception (OR vs. patch, pill, or ring 1.37). 

Study details: The data come from surveys of 32,098 women aged 18-44 years who participated in the 2017 Behavioral Risk Factor Surveillance System, 16% of whom had at least one potential contraindication to estrogen.

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Source: Erly SJ et al. J Womens Health. 2021 Sep 1. doi: 10.1089/jwh.2020.8905. 

Key clinical point: Expulsion rates were similar for women using a 52 mg levonorgestrel intrauterine system for heavy menstrual bleeding and those who used it for contraception; a history of cesarean delivery increased the risk of expulsion in both groups.

Major finding:  Expulsion of the device occurred in 548 of the women with heavy menstrual bleeding (5.6%) and 315 of the women using the device for contraception (5.6%). The odds ratio for expulsion for women with a history of cesarean delivery in either group was 1.93.

Study details: The data come from an audit of 548 women who used a 52 mg levonorgestrel intrauterine system to manage heavy menstrual bleeding and 5,655 who used it for contraception.

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Source: Furlan RM et al. Contraception. 2021 Sep 5. doi: 10.1016/j.contraception.2021.09.001.

Key clinical point: Expulsion rates were similar for women using a 52 mg levonorgestrel intrauterine system for heavy menstrual bleeding and those who used it for contraception; a history of cesarean delivery increased the risk of expulsion in both groups.

Major finding:  Expulsion of the device occurred in 548 of the women with heavy menstrual bleeding (5.6%) and 315 of the women using the device for contraception (5.6%). The odds ratio for expulsion for women with a history of cesarean delivery in either group was 1.93.

Study details: The data come from an audit of 548 women who used a 52 mg levonorgestrel intrauterine system to manage heavy menstrual bleeding and 5,655 who used it for contraception.

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Source: Furlan RM et al. Contraception. 2021 Sep 5. doi: 10.1016/j.contraception.2021.09.001.

Key clinical point: Expulsion rates were similar for women using a 52 mg levonorgestrel intrauterine system for heavy menstrual bleeding and those who used it for contraception; a history of cesarean delivery increased the risk of expulsion in both groups.

Major finding:  Expulsion of the device occurred in 548 of the women with heavy menstrual bleeding (5.6%) and 315 of the women using the device for contraception (5.6%). The odds ratio for expulsion for women with a history of cesarean delivery in either group was 1.93.

Study details: The data come from an audit of 548 women who used a 52 mg levonorgestrel intrauterine system to manage heavy menstrual bleeding and 5,655 who used it for contraception.

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Source: Furlan RM et al. Contraception. 2021 Sep 5. doi: 10.1016/j.contraception.2021.09.001.

Key clinical point: Daily use of 75 µg norgestrel was effective contraception for both breastfeeding and non-breastfeeding women

Major finding:  Overall failure rates for non-breastfeeding women using 75 µg/day norgestrel ranged from 0-2.4/100 woman-years for an aggregate Pearl Index of 2.2. Among breastfeeding women, the 12-month life table cumulative pregnancy rates for norgestrel ranged from 0-3.4.

Study details: The data come from 13 studies of women who used a progestogen-only pill containing 75 µg/day norgestrel. The review included 6 studies with data on 3,144 women who were not breastfeeding and 7 studies with data on 5,258 women who were breastfeeding during part of the follow-up period. The women were followed for a total of 35,319 months.  

Disclosures: The study received no outside funding. Lead author Dr. Anna Glasier and coauthor Stephanie Sober disclosed serving as independent consultants to HRA-Pharma.

Source: Glasier A et al. Contraception. 2021 Sep 6. doi: 10.1016/j.contraception.2021.08.016.

Key clinical point: Daily use of 75 µg norgestrel was effective contraception for both breastfeeding and non-breastfeeding women

Major finding:  Overall failure rates for non-breastfeeding women using 75 µg/day norgestrel ranged from 0-2.4/100 woman-years for an aggregate Pearl Index of 2.2. Among breastfeeding women, the 12-month life table cumulative pregnancy rates for norgestrel ranged from 0-3.4.

Study details: The data come from 13 studies of women who used a progestogen-only pill containing 75 µg/day norgestrel. The review included 6 studies with data on 3,144 women who were not breastfeeding and 7 studies with data on 5,258 women who were breastfeeding during part of the follow-up period. The women were followed for a total of 35,319 months.  

Disclosures: The study received no outside funding. Lead author Dr. Anna Glasier and coauthor Stephanie Sober disclosed serving as independent consultants to HRA-Pharma.

Source: Glasier A et al. Contraception. 2021 Sep 6. doi: 10.1016/j.contraception.2021.08.016.

Key clinical point: Daily use of 75 µg norgestrel was effective contraception for both breastfeeding and non-breastfeeding women

Major finding:  Overall failure rates for non-breastfeeding women using 75 µg/day norgestrel ranged from 0-2.4/100 woman-years for an aggregate Pearl Index of 2.2. Among breastfeeding women, the 12-month life table cumulative pregnancy rates for norgestrel ranged from 0-3.4.

Study details: The data come from 13 studies of women who used a progestogen-only pill containing 75 µg/day norgestrel. The review included 6 studies with data on 3,144 women who were not breastfeeding and 7 studies with data on 5,258 women who were breastfeeding during part of the follow-up period. The women were followed for a total of 35,319 months.  

Disclosures: The study received no outside funding. Lead author Dr. Anna Glasier and coauthor Stephanie Sober disclosed serving as independent consultants to HRA-Pharma.

Source: Glasier A et al. Contraception. 2021 Sep 6. doi: 10.1016/j.contraception.2021.08.016.

Key clinical point: The contraception workforce in the United States varies by geography, provider specialty, and Medicaid acceptance, and gaps remain in the provision of IUDs and implants.

Major finding:  Approximately 73% of obgyns and nurse midwives prescribed the pill, patch, or ring, compared to 51% of family medicine physicians, 32% of pediatricians, and 20% of internal medicine physicians. A majority of obgyns provided contraception to Medicaid patients, ranging from 84% in the District of Columbia to 100% in North Dakota.

Study details: The data come from an observational study of the contraception workforce in the United States. A team of researchers created a comprehensive database of the workforce in the United States that provides six contraception types: intrauterine device (IUD), implant, shot (depot medroxyprogesterone acetate, or DMPA), oral contraception, hormonal patch, and vaginal ring. 

Disclosures: The study was funded by a private foundation that wishes to remain anonymous. The researchers had no financial conflicts to disclose.

Source: Chen C et al. Am J Obstet Gynecol. 2021 Aug 18. doi: 10.1016/j.ajog.2021.08.015.

Key clinical point: The contraception workforce in the United States varies by geography, provider specialty, and Medicaid acceptance, and gaps remain in the provision of IUDs and implants.

Major finding:  Approximately 73% of obgyns and nurse midwives prescribed the pill, patch, or ring, compared to 51% of family medicine physicians, 32% of pediatricians, and 20% of internal medicine physicians. A majority of obgyns provided contraception to Medicaid patients, ranging from 84% in the District of Columbia to 100% in North Dakota.

Study details: The data come from an observational study of the contraception workforce in the United States. A team of researchers created a comprehensive database of the workforce in the United States that provides six contraception types: intrauterine device (IUD), implant, shot (depot medroxyprogesterone acetate, or DMPA), oral contraception, hormonal patch, and vaginal ring. 

Disclosures: The study was funded by a private foundation that wishes to remain anonymous. The researchers had no financial conflicts to disclose.

Source: Chen C et al. Am J Obstet Gynecol. 2021 Aug 18. doi: 10.1016/j.ajog.2021.08.015.

Key clinical point: The contraception workforce in the United States varies by geography, provider specialty, and Medicaid acceptance, and gaps remain in the provision of IUDs and implants.

Major finding:  Approximately 73% of obgyns and nurse midwives prescribed the pill, patch, or ring, compared to 51% of family medicine physicians, 32% of pediatricians, and 20% of internal medicine physicians. A majority of obgyns provided contraception to Medicaid patients, ranging from 84% in the District of Columbia to 100% in North Dakota.

Study details: The data come from an observational study of the contraception workforce in the United States. A team of researchers created a comprehensive database of the workforce in the United States that provides six contraception types: intrauterine device (IUD), implant, shot (depot medroxyprogesterone acetate, or DMPA), oral contraception, hormonal patch, and vaginal ring. 

Disclosures: The study was funded by a private foundation that wishes to remain anonymous. The researchers had no financial conflicts to disclose.

Source: Chen C et al. Am J Obstet Gynecol. 2021 Aug 18. doi: 10.1016/j.ajog.2021.08.015.